Midkiff KD, Gilsenan AW, Martin RD, Wu Y, Masica D, Andrews EB. The impact of patient access on post marketing drug safety studies using cancer registry data. Poster presented at the 25th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2009. Providence, RI. [abstract] Pharmacoepidemiol Drug Saf. 2009 Aug 14; 18(Suppl 1):S169. doi: 10.1002/pds.1806
Gilsenan AW, Andrews EB, Martin R, Midkiff KD. Charting a new course: the critical role of cancer registries in the science of drug safety. Poster presented at the North American Association of Central Cancer Registries Annual Meeting; June 2009.
Midkiff KD, Gilsenan AW, Martin RD, Andrews EB, Wu Y, Masica D. The new world in cancer surveillance: accommodating patient privacy and drug safety studies. Presented at the NAACCR; June 2009.
Midkiff KD, Martin RD, Gilsenan AW, Masica D, Andrews EB. New directions in using cancer registry data 5–year results from a patient drug safety surveillance study of adult osteosarcoma. Presented at the North American Association of Central Cancer Registries Annual Meeting; June 2009.
Midkiff KD, Gilsenan AW, Martin RD, Wu Y, Masica N, Andrews EB. Characteristics of patients in a post marketing osteosarcoma surveillance study. Presented at the 34th Meeting of the Scandinavian Sarcoma Group; May 2009.
Von Scheele BG, Martin RD, Gilsenan AW, Ceberg J, Andrews EB, Masica D, Alvegård T. The European postmarketing adult osteosarcoma surveillance study characteristics of patients: a preliminary report. Acta Orthop. 2009;80:67-74.